what happens if you stop taking tirzepatide 6 Things That Can Happen When Mounjaro, Zepbound Rebound Weight Gain After Stopping

BMI is currently used as a general screening tool to diagnose overweight (BMI 25 to 29.9 kg/m 2 ) and obesity (BMI 30 kg/m 2 ), but these BMI cutoffs do not capture risk of adiposity among varied ethnic groups, nor do they identify individual CMD risk

LLC in December 2025

A comprehensive meta-analysis published in 2022 examining data from randomized controlled trials involving GLP-1 receptor agonists found no statistically significant increase in overall cancer incidence

This study builds on Ro's strong foundation of clinical research, including eight abstracts that the company presented at ObesityWeek 2025 in November, spanning topics from the use of AI to improve the patient experience, such as an evaluation of Ro's LLM-enabled adverse event reporting tool, to outcomes among patients treated with GLP-1s, such as those with osteoarthritis

GLP-1 receptor activation Reduces appetite via central signaling, slows gastric emptying, increases glucose-dependent insulin secretion, and suppresses glucagon during hyperglycemia